192 related articles for article (PubMed ID: 32496149)
1. Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.
Charo LM; Homer MV; Natarajan L; Haunschild C; Chung K; Mao JJ; DeMichele AM; Su HI
J Obstet Gynaecol; 2021 Apr; 41(3):447-452. PubMed ID: 32496149
[TBL] [Abstract][Full Text] [Related]
2. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.
Su HI; Sammel MD; Velders L; Horn M; Stankiewicz C; Matro J; Gracia CR; Green J; DeMichele A
Fertil Steril; 2010 Jul; 94(2):645-54. PubMed ID: 19376514
[TBL] [Abstract][Full Text] [Related]
3. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
4. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Yao S; Barlow WE; Albain KS; Choi JY; Zhao H; Livingston RB; Davis W; Rae JM; Yeh IT; Hutchins LF; Ravdin PM; Martino S; Lyss AP; Osborne CK; Abeloff M; Hortobagyi GN; Hayes DF; Ambrosone CB
Clin Cancer Res; 2010 Dec; 16(24):6169-76. PubMed ID: 21169260
[TBL] [Abstract][Full Text] [Related]
5. Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.
Kumaraswami K; Katkam SK; Aggarwal A; Sharma A; Manthri R; Kutala VK; Rajasekhar L
Pharmacogenomics; 2017 Oct; 18(15):1401-1411. PubMed ID: 28976264
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2009 Jan; 67(1):50-60. PubMed ID: 19076156
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.
Singh G; Saxena N; Aggarwal A; Misra R
J Rheumatol; 2007 Apr; 34(4):731-3. PubMed ID: 17407229
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2E1, GSTA1 and GSTP1 gene variants on serum alpha glutathione S-transferase level in patients undergoing anaesthesia.
Mikstacki A; Skrzypczak-Zielinska M; Zakerska-Banaszak O; Tamowicz B; Skibinska M; Molinska-Glura M; Szalata M; Slomski R
BMC Med Genet; 2016 May; 17(1):40. PubMed ID: 27179909
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
Gor PP; Su HI; Gray RJ; Gimotty PA; Horn M; Aplenc R; Vaughan WP; Tallman MS; Rebbeck TR; DeMichele A
Breast Cancer Res; 2010; 12(3):R26. PubMed ID: 20459744
[TBL] [Abstract][Full Text] [Related]
10. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
[TBL] [Abstract][Full Text] [Related]
11. Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients.
Romero A; Martín M; Oliva B; de la Torre J; Furio V; de la Hoya M; García-Sáenz JA; Moreno A; Román JM; Diaz-Rubio E; Caldés T
Ann Oncol; 2012 Jul; 23(7):1750-6. PubMed ID: 22052985
[TBL] [Abstract][Full Text] [Related]
12. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment.
Sweeney C; Ambrosone CB; Joseph L; Stone A; Hutchins LF; Kadlubar FF; Coles BF
Int J Cancer; 2003 Mar; 103(6):810-4. PubMed ID: 12516103
[TBL] [Abstract][Full Text] [Related]
13. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
Afsar NA; Ufer M; Haenisch S; Remmler C; Mateen A; Usman A; Ahmed KZ; Ahmad HR; Cascorbi I
Eur J Clin Pharmacol; 2012 Apr; 68(4):389-95. PubMed ID: 22012257
[TBL] [Abstract][Full Text] [Related]
14. Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
Zhou X; Wang X; Song Q; Yang H; Zhu X; Yu J; Song G; Di L; Ren J; Shao H; Lyerly HK
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):914-22. PubMed ID: 26396136
[TBL] [Abstract][Full Text] [Related]
15. The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China.
Ge J; Tian AX; Wang QS; Kong PZ; Yu Y; Li XQ; Cao XC; Feng YM
PLoS One; 2013; 8(6):e67589. PubMed ID: 23826324
[TBL] [Abstract][Full Text] [Related]
16. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
Ludovini V; Antognelli C; Rulli A; Foglietta J; Pistola L; Eliana R; Floriani I; Nocentini G; Tofanetti FR; Piattoni S; Minenza E; Talesa VN; Sidoni A; Tonato M; Crinò L; Gori S
BMC Cancer; 2017 Jul; 17(1):502. PubMed ID: 28747156
[TBL] [Abstract][Full Text] [Related]
17. [Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer].
Tang JH; Zhao JH; Wu JZ; Lu JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):108-13. PubMed ID: 19538885
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Helsby N; Yong M; Burns K; Findlay M; Porter D
Cancer Chemother Pharmacol; 2021 Sep; 88(3):533-542. PubMed ID: 34114066
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.
Damkier P; Kjærsgaard A; Barker KA; Cronin-Fenton D; Crawford A; Hellberg Y; Janssen EAM; Langefeld C; Ahern TP; Lash TL
Sci Rep; 2017 Aug; 7(1):7727. PubMed ID: 28798474
[TBL] [Abstract][Full Text] [Related]
20. Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy.
Thota K; Prasad K; Basaveswara Rao MV
Asian Pac J Cancer Prev; 2018 Feb; 19(2):343-350. PubMed ID: 29479969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]